Functional mismatch repair and inactive p53 drive sensitization of colorectal cancer cells to irinotecan via the IAP antagonist BV6
Sign Up to like & getrecommendations! Published in 2019 at "Archives of Toxicology"
DOI: 10.1007/s00204-019-02513-7
Abstract: A common strategy to overcome acquired chemotherapy resistance is the combination of a specific anticancer drug (e.g., topoisomerase I inhibitor irinotecan) together with a putative sensitizer. The purpose of this study was to analyze the… read more here.
Keywords: cells irinotecan; bv6; p53; mismatch repair ... See more keywords